Spinal Cord Stimulation — Procedure Guide, Recovery & Risks | MyMedicPlus

Spinal cord stimulation (SCS) is an implantable neuromodulation therapy that delivers programmable, reversible electrical impulses to the dorsal columns of the spinal cord via epidurally placed lead electrodes connected to an implantable pulse generator (IPG) positioned subcutaneously in the abdomen or buttock. By modulating pain-processing neural circuits in the dorsal horn and ascending spinal pathways, SCS interrupts the transmission of pain signals to the brain — providing analgesia without the systemic side effects of opioid and other analgesic medications.

Conventional SCS (tonic stimulation) produces a tingling paraesthesia (tingling sensation) in the area of pain, replacing the pain signal with a more tolerable sensation. Newer SCS modalities — high-frequency SCS (HF10, 10,000 Hz, Nevro Senza system) and burst SCS (Abbott BurstDR) — provide paraesthesia-free analgesia by using waveforms that suppress pain without producing the tingling sensation, allowing effective treatment of axial low back pain which was previously less responsive to tonic SCS.

SCS is a reversible, adjustable therapy — parameters can be reprogrammed non-invasively, the device can be removed if no longer beneficial, and stimulation can be initiated or stopped with a patient-controlled handheld programmer. Unlike opioids, SCS therapy does not cause dependence, tolerance, constipation, or respiratory depression. It is endorsed by NICE (UK), FDA (US), and major pain societies as an evidence-based treatment for specific chronic pain conditions.

Spinal cord stimulation is indicated for selected patients with chronic, severe, refractory neuropathic pain that has failed to respond adequately to comprehensive conservative management, including structured physiotherapy, psychological pain management (CBT), analgesic medications at optimised doses (gabapentinoids, SNRIs, tricyclics), and interventional procedures (nerve blocks, steroid injections).

Primary indications include: failed back surgery syndrome (FBSS) — persistent or recurrent radicular leg pain after one or more spinal surgeries (one of the most common and evidence-supported indications, with the PROCESS and SPORT RCTs demonstrating superiority over reoperation); complex regional pain syndrome (CRPS Type I and II) — formerly reflex sympathetic dystrophy, characterised by disproportionate burning pain, allodynia, and autonomic changes (the strongest SCS evidence base); refractory angina (no option angina) — reducing anginal episodes and improving quality of life when revascularisation is not possible; and peripheral vascular disease — improving limb perfusion and reducing rest pain in non-reconstructable peripheral arterial disease.

Patient selection includes comprehensive psychological assessment (ensuring absence of untreated depression, active substance misuse, or major psychiatric comorbidity that would impair outcome), a successful test stimulation phase, and realistic patient expectations of the goals of SCS (pain reduction, not elimination; improved function and quality of life).

The SCS implant procedure uses the same two-stage approach as sacral neuromodulation to allow a trial period.

Stage 1 — Percutaneous Lead Trial: The patient is positioned prone under fluoroscopic guidance. A Tuohy needle (14-gauge epidural needle) is inserted into the epidural space at the L1/L2 or L2/L3 interspace using a paramedian approach. A cylindrical multi-contact lead (usually 8 contacts, 1 mm spaced) is steered under fluoroscopy through the epidural space to the target dorsal column level: T8/T9 for leg-predominant pain, C2–C4 for arm pain, or specific vertebral levels for other conditions. The patient is asked during lead placement (usually under conscious sedation) whether the paraesthesia covers the distribution of their pain — optimising lead position before securing.

The lead is anchored to the interspinous ligament and tunnelled to an exit site at the flank where it connects to an external trial stimulator worn for 5–14 days. During the trial, the patient uses a diary to record pain scores, activity levels, sleep, and analgesic use. A greater than 50% pain reduction is the standard threshold for proceeding to permanent implant.

Stage 2 — Permanent Implant (4–6 weeks after successful trial): Under general or deep sedation, the trial lead is replaced with a permanent lead (or paddle lead for better coverage) and connected subcutaneously to the IPG implanted in the abdomen or buttock. Rechargeable IPGs last 7–10 years; non-rechargeable IPGs 3–5 years before requiring replacement.

Stage 1 is performed as day surgery or with one overnight stay; patients are discharged with the external stimulator. Activities are restricted to light daily activities during the trial phase to prevent lead migration. Showering is permitted with waterproof dressing covers; no immersion bathing or swimming.

After Stage 2 permanent implant, discharge is on the same day or next morning. The wound heals over 2 weeks; heavy lifting (greater than 5 kg) and bending are avoided for 6 weeks to allow the lead to fibrose securely in position and prevent migration. Normal light activities resume gradually. MRI is permissible with MRI-conditional SCS systems under specific protocols, requiring programming adjustments around each scan.

Programming optimisation is performed at 2 and 6 weeks using a programmer interface, adjusting amplitude, frequency, pulse width, and electrode configuration to achieve optimal pain relief. Regular follow-up allows ongoing parameter adjustments as pain patterns change. Patients control stimulation delivery (on/off, preset programmes) with a handheld programmer. IPG battery replacement (for non-rechargeable devices) requires a minor surgical procedure every 3–5 years. Long-term, multidisciplinary pain management continues alongside SCS — the device is one component of a comprehensive programme.

Lead migration is the most common hardware complication, occurring in 10–15% of percutaneous leads, causing sudden loss of pain coverage and requiring repositioning under fluoroscopy. Paddle leads (surgically implanted via a small laminotomy) have a lower migration rate but require a more invasive procedure.

Device infection occurs in 3–5% and may require partial or complete device explantation, with reimplantation delayed until infection is completely cleared. Epidural haematoma — potentially causing spinal cord compression — is rare (less than 0.1%) but is a medical emergency if it occurs; anticoagulants must be safely held peri-procedurally. Seroma at the IPG site is common (10–15%) and usually resolves with aspiration and pressure.

Lead fracture, component failure, and connection malfunction occur over time, typically requiring minor revision under local anaesthesia. Loss of therapy efficacy (tolerance) may occur with tonic stimulation, addressed by switching to burst or HF10 programmes. Hardware revision rates of 20–30% over 5 years are reported in most series, reflecting the range of lead, battery, and programme-related issues that accumulate with long-term use.

50–70% of appropriately selected SCS patients achieve greater than 50% pain reduction at 12-month follow-up, significantly exceeding what is achievable with best medical management alone. The PROCESS RCT demonstrated SCS superior to reoperation for FBSS in achieving 50% pain reduction (48% vs 9% at 6 months), with sustained superiority at 24 months.

HF10 SCS (10,000 Hz, Nevro Senza) demonstrated superiority over conventional SCS in the SENZA-RCT for both back and leg pain: 84% responder rate (greater than 50% pain reduction) for back pain versus 43% for conventional SCS — a landmark result that drove adoption of high-frequency SCS.

Beyond pain reduction, SCS therapy consistently improves: physical function and daily activity levels, sleep quality, mood, and quality of life (measured by EQ-5D and SF-36); opioid consumption is reduced by 20–40% enabling dose reduction or cessation; return to work rates improve significantly compared to continued medical management. The economic analysis demonstrates SCS cost-effectiveness within 2–3 years when device costs are compared to ongoing medication, GP visits, hospital admissions, and lost productivity costs. NICE guidelines (IPG063) and NHS England endorse SCS for FBSS and CRPS as evidence-based cost-effective therapies.